Latest news with #VersantVentures
National Post
24-04-2025
- Business
- National Post
Granite Bio Debuts With $100 Million of Capital
Article content -Clinical-stage company targeting fundamental drivers of inflammation, autoimmunity and fibrosis, founded by Versant Ventures and Novartis Venture Fund- Article content Article content BASEL, Switzerland & SAN FRANCISCO — Granite Bio AG, a clinical-stage immunology company, has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund, and a $70 million Series B led by Forbion and Sanofi Ventures. Article content Granite's pipeline features two first-in-class antibodies targeting multiple autoimmune diseases that address large market opportunities. Article content GRT-001 depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. In non-human primate studies, GRT-001 efficiently and dose-dependently depleted pro-inflammatory monocytes. Treatment was well tolerated and spared tissue-resident macrophages, which are important for tissue homeostasis. GRT-001 is currently in Phase 1a testing in healthy volunteers and is expected to enter a Phase 1b trial in patients with inflammatory bowel disease later this year. Article content GRT-002 blocks interleukin-3, a key player in autoimmune inflammation and type II inflammation, offering a new approach to treating itch and allergy. The molecule is in preclinical development and is expected to enter clinical trials in 2026. Article content Both of Granite's lead molecules were developed in collaboration with Versant's Ridgeline Discovery Engine in Basel, Switzerland, and originated from the laboratories of Professor and Scientific Co-Founder Matthias Mack at University of Regensburg. Article content 'Granite is pioneering a new approach to tackling inflammation, autoimmunity, and fibrosis by addressing fundamental disease drivers at their source,' said Patrick Loustau, president and CEO. 'With the support of an exceptional investor syndicate and a world-class team, we are advancing a pipeline of first-in-class therapies with the potential to transform patient outcomes. I look forward to working with the management team to deliver groundbreaking treatments that address the urgent unmet needs in immunology and beyond.' Article content 'Despite multiple immunology-based therapeutic approaches currently commercialized, patients with inflammatory disorders continue to experience a lack of symptom control and relapse,' said Nigel Sheail, partner at Versant and Granite board member. 'Granite has the potential to enable a real step change for patients with its innovative programs that target key fundamental disease pathways.' Article content 'I am proud to support Granite as it advances its lead assets using a truly differentiated approach to tackling inflammation at its root,' said Rogier Rooswinkel, Ph.D., General Partner at Forbion and Granite board member. 'With the strength of this investor syndicate and an exceptional leadership team, Granite is well-positioned to drive its pipeline forward and deliver meaningful new therapies for patients.' Article content Granite is led by an experienced team including: Article content Patrick Loustau, president and CEO, brings broad and successful experience in building and developing organizations in biotech and pharmaceutical companies. Prior to joining Granite Bio, he was the CBO of Amolyt Pharma until its acquisition by Alexion (AstraZeneca Rare Disease) for up to $1.05B in July 2024. Before Amolyt, he was CEO of Zumbro Discovery Inc. and president of Zafgen Inc. Earlier in his career, he led global organizations at Bristol Myers-Squibb and Novo Nordisk. Dominik Hartl, M.D., CMO, has extensive background in immunology and fibrosis drug development. He previously served as CMO for Quell Therapeutics, a company specialized in immune-mediated diseases. Before that, he held leadership positions in Immunology Drug Development/Translational Medicine at Novartis (NIBR/Immunology), Roche (pRED/I2O) and Galapagos Pharma. Dominik is a board-certified M.D. and holds an adjunct professorship in Pediatric Immunology at University of Tübingen. Gijs van den Brink, M.D., Ph.D., CSO, possesses deep academic and industry experience in immunology and IBD. Currently also an Operating Partner at Forbion, he previously served as SVP and Global Head of Immunology, CVM, ID, and Ophthalmology Discovery and Early Development at Roche. Before that, Dr. van den Brink was head of Immunology discovery and early and late-stage clinical development at GlaxoSmithKline plc. Gijs previously was a gastroenterologist and professor of experimental gastroenterology and co-authored over 150 peer-reviewed scientific publications. Eliot Forster, chairperson of the board, has more than 30 years of extensive biotech experience from both executive and non-executive roles. He was CEO of F-star Therapeutics until its acquisition by inovX Pharma LTD in March 2023, and formerly CEO of Immunocore. Eliot is currently CEO of Levicept LTD, non-executive chair of Tessellate BIO and a director at Immatics.
Yahoo
17-04-2025
- Business
- Yahoo
UnitedHealth Group Incorporated (UNH): Among the Innovative Healthcare Stocks to Watch in 2025
We recently published a list of the . In this article, we are going to take a look at where UnitedHealth Group Incorporated (NYSE:UNH) stands against the other innovative healthcare stocks to watch in 2025. In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private health insurance is the two leading causes of this increase. The impact of tariffs on this continuing trend has become a significant bone of contention in the healthcare industry as more and more US corporations turn to China for agreements on the next breakthrough chemical, whether in the areas of obesity or cancer. Carlo Rizzuto, managing director of Versant Ventures, spoke on CNBC's "Fast Money" on February 7 about the impact of tariffs on healthcare. Rizzuto says that tariffs may impact the sector in two ways. Products made in China and sold in the US or other countries would be the first. The industry would need to watch how the tariffs are used in the market to comprehend how they would impact such trade operations. Second, and more precisely, the US healthcare industry relies heavily on China as a basis for contract production and research. Consequently, anything that raises that price is probably going to make the market more difficult. Cost hikes won't help the healthcare industry's management, which is already under pressure from investors. Speaking on China's enormous impact in the pharmaceutical and healthcare sectors, Rizzuto said that the vast majority of healthcare companies use a Chinese CRO or manufacturing partner in some capacity during the research and development phase. As a result, it significantly affects how the nation's biotech and pharmaceutical industries function. This trend is rather common in businesses of all sizes. In other words, the lack of infrastructure to facilitate the transfer prevents healthcare corporations from reshoring all of their externalized R&D and production to the United States. Therefore, it is hard to imagine how such a large-scale reshoring might occur. The amount of tariffs imposed can be used to determine the expenses of achieving this objective linearly. According to McKinsey, healthcare EBITDA will rise from a starting point of $676 billion in 2023 to $987 billion in 2028 at a 7% CAGR. Recovery from post-pandemic lows is anticipated to spur progress in several areas, even though development is anticipated to be faster in some (such as specialized pharmacy and HST). Software platforms are essential to the healthcare ecosystem because they let payers and providers operate more effectively in a complex environment. By automating procedures, fostering data connectivity, and producing actionable insights, technological innovation (such as generative AI and machine learning) keeps providing opportunities for stakeholders from all industries. McKinsey predicts that increased utilization and pipeline expansion (as in cancer) will result in a considerable increase in specialty pharmacy income. Specialty pharmacy profit pools are continuing to grow as a result of the rise in the use of specialty medications. For this article, we began by screening the top holdings of the iShares U.S. Healthcare ETF (IYH) to focus on prominent companies within the U.S. healthcare sector. From this list, we selected the top 10 holdings based on their weight in the ETF portfolio. We then ranked these stocks according to the number of hedge funds holding positions in each company as of Q4 2024, based on data from Insider Monkey's hedge fund tracking database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A senior healthcare professional giving advice to a patient in a clinic. Number of Hedge Fund Holders: 150 UnitedHealth Group Incorporated (NYSE:UNH) tops our list for being one of the best healthcare stocks. It operates in the healthcare sector in the US and globally, with four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The board of directors approved a $2.10 quarterly dividend per share on February 24. In line with its previous forecasts, UnitedHealth Group Incorporated (NYSE:UNH) produced approximately $400 billion in revenue in 2024 and adjusted earnings per share of $27.66. Throughout the year, it concentrated on improving the customer experience, speeding up innovation, and honing its business plan for sustained expansion to solidify its position going forward. Over $16 billion was distributed to shareholders in the form of dividends and share repurchases, while over $17 billion was allocated to expansion initiatives. The company anticipates operational cash flow to be 1.2 times its net income in 2025, or around $33 billion. Optum Rx, a division of UnitedHealth Group Incorporated (NYSE:UNH), announced modifications to its payment models on March 20 to better reflect pharmacy expenses impacted by manufacturer pricing. The changes go into effect right away, and they will be fully implemented by January 2028. More than 24,000 independent community pharmacies in Optum Rx's non-affiliated network will profit from this change, which attempts to give customers more reliable and reasonably priced prices. Overall UNH ranks 1st among the innovative healthcare stocks to watch in 2025. While we acknowledge the potential of UNH as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than UNH but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at .
Yahoo
17-04-2025
- Business
- Yahoo
Eli Lilly and Company (LLY): Among the Innovative Healthcare Stocks to Watch in 2025
In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private health insurance is the two leading causes of this increase. The impact of tariffs on this continuing trend has become a significant bone of contention in the healthcare industry as more and more US corporations turn to China for agreements on the next breakthrough chemical, whether in the areas of obesity or cancer. Carlo Rizzuto, managing director of Versant Ventures, spoke on CNBC's "Fast Money" on February 7 about the impact of tariffs on healthcare. Rizzuto says that tariffs may impact the sector in two ways. Products made in China and sold in the US or other countries would be the first. The industry would need to watch how the tariffs are used in the market to comprehend how they would impact such trade operations. Second, and more precisely, the US healthcare industry relies heavily on China as a basis for contract production and research. Consequently, anything that raises that price is probably going to make the market more difficult. Cost hikes won't help the healthcare industry's management, which is already under pressure from investors. Speaking on China's enormous impact in the pharmaceutical and healthcare sectors, Rizzuto said that the vast majority of healthcare companies use a Chinese CRO or manufacturing partner in some capacity during the research and development phase. As a result, it significantly affects how the nation's biotech and pharmaceutical industries function. This trend is rather common in businesses of all sizes. In other words, the lack of infrastructure to facilitate the transfer prevents healthcare corporations from reshoring all of their externalized R&D and production to the United States. Therefore, it is hard to imagine how such a large-scale reshoring might occur. The amount of tariffs imposed can be used to determine the expenses of achieving this objective linearly. According to McKinsey, healthcare EBITDA will rise from a starting point of $676 billion in 2023 to $987 billion in 2028 at a 7% CAGR. Recovery from post-pandemic lows is anticipated to spur progress in several areas, even though development is anticipated to be faster in some (such as specialized pharmacy and HST). Software platforms are essential to the healthcare ecosystem because they let payers and providers operate more effectively in a complex environment. By automating procedures, fostering data connectivity, and producing actionable insights, technological innovation (such as generative AI and machine learning) keeps providing opportunities for stakeholders from all industries. McKinsey predicts that increased utilization and pipeline expansion (as in cancer) will result in a considerable increase in specialty pharmacy income. Specialty pharmacy profit pools are continuing to grow as a result of the rise in the use of specialty medications. For this article, we began by screening the top holdings of the iShares U.S. Healthcare ETF (IYH) to focus on prominent companies within the U.S. healthcare sector. From this list, we selected the top 10 holdings based on their weight in the ETF portfolio. We then ranked these stocks according to the number of hedge funds holding positions in each company as of Q4 2024, based on data from Insider Monkey's hedge fund tracking database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). An array of pharmaceutical pills with the company's logo on the bottle. Number of Hedge Fund Holders: 115 Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company based in Indianapolis, develops and markets medications across the US, Europe, Japan, China, and other regions. The company said on February 26 that it would invest at least $27 billion to construct four new manufacturing facilities in the US to meet the increasing demand for its diabetes and weight loss medications and to further the development of new drugs. Eli Lilly and Company (NYSE:LLY) had a great year in 2024, exceeding its initial projection by $4 billion and seeing a 32% increase in annual revenue over the previous year. Revenue increased by 45% in just the fourth quarter due to the success of recently released items, which brought in over $3.1 billion. Mounjaro and Zepbound were particularly well-liked. Along with strong growth in immunology, neuroscience, and oncology, the business also witnessed a 20% gain in revenue from its non-incretin portfolio. A positive product mix helped the gross margin increase to 83.2% in the fourth quarter. Investments in early and late-stage initiatives resulted in an 18% increase in research and development costs. Due to its robust sales of new items, operating income more than doubled to $5.6 billion. Eli Lilly and Company (NYSE:LLY) declared on February 28 that Jaypirca (pirtobrutinib), a reversible Bruton's tyrosine kinase (BTK) inhibitor, has been recommended for approval by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use. Adults with relapsed or refractory chronic lymphocytic leukemia who have already taken a BTK inhibitor are the target population for this treatment. The recommendation is currently awaiting the final evaluation by the European Commission, which may be a major impetus for the company if it is approved. Overall LLY ranks 2nd among the innovative healthcare stocks to watch in 2025. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Sign in to access your portfolio
Yahoo
17-04-2025
- Business
- Yahoo
Thermo Fisher Scientific Inc. (TMO): Among the Innovative Healthcare Stocks to Watch in 2025
In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private health insurance is the two leading causes of this increase. The impact of tariffs on this continuing trend has become a significant bone of contention in the healthcare industry as more and more US corporations turn to China for agreements on the next breakthrough chemical, whether in the areas of obesity or cancer. Carlo Rizzuto, managing director of Versant Ventures, spoke on CNBC's "Fast Money" on February 7 about the impact of tariffs on healthcare. Rizzuto says that tariffs may impact the sector in two ways. Products made in China and sold in the US or other countries would be the first. The industry would need to watch how the tariffs are used in the market to comprehend how they would impact such trade operations. Second, and more precisely, the US healthcare industry relies heavily on China as a basis for contract production and research. Consequently, anything that raises that price is probably going to make the market more difficult. Cost hikes won't help the healthcare industry's management, which is already under pressure from investors. Speaking on China's enormous impact in the pharmaceutical and healthcare sectors, Rizzuto said that the vast majority of healthcare companies use a Chinese CRO or manufacturing partner in some capacity during the research and development phase. As a result, it significantly affects how the nation's biotech and pharmaceutical industries function. This trend is rather common in businesses of all sizes. In other words, the lack of infrastructure to facilitate the transfer prevents healthcare corporations from reshoring all of their externalized R&D and production to the United States. Therefore, it is hard to imagine how such a large-scale reshoring might occur. The amount of tariffs imposed can be used to determine the expenses of achieving this objective linearly. According to McKinsey, healthcare EBITDA will rise from a starting point of $676 billion in 2023 to $987 billion in 2028 at a 7% CAGR. Recovery from post-pandemic lows is anticipated to spur progress in several areas, even though development is anticipated to be faster in some (such as specialized pharmacy and HST). Software platforms are essential to the healthcare ecosystem because they let payers and providers operate more effectively in a complex environment. By automating procedures, fostering data connectivity, and producing actionable insights, technological innovation (such as generative AI and machine learning) keeps providing opportunities for stakeholders from all industries. McKinsey predicts that increased utilization and pipeline expansion (as in cancer) will result in a considerable increase in specialty pharmacy income. Specialty pharmacy profit pools are continuing to grow as a result of the rise in the use of specialty medications. For this article, we began by screening the top holdings of the iShares U.S. Healthcare ETF (IYH) to focus on prominent companies within the U.S. healthcare sector. From this list, we selected the top 10 holdings based on their weight in the ETF portfolio. We then ranked these stocks according to the number of hedge funds holding positions in each company as of Q4 2024, based on data from Insider Monkey's hedge fund tracking database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A workstation in a research lab stocked with laboratory products and services. Number of Hedge Fund Holders: 100 Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics are its four business divisions. Thermo Fisher Scientific Inc. (NYSE:TMO) is growing steadily, and in fiscal Q4 2024, it recorded $11.4 billion in revenue, which is a 5% increase from the previous year. Given that it produced more than $7.3 billion in free cash flow in fiscal 2024, its solid cash position further enhances its reputation. After growing its dividends for eight years in a row, the business also has a high dividend yield. Its potential to provide value to shareholders was demonstrated by the 250% outperformance of the sector median over two years. Thermo Fisher Scientific Inc. (NYSE:TMO) has a competitive market position because of its long-standing client connections, high switching costs, and leadership in the life sciences, positioning itself among the best healthcare stocks. Its tools and supplies are particularly helpful in the development of new drugs. In the upcoming years, it's management anticipates high-single-digit revenue growth, and the company anticipates continuing its steady expansion. Because of its recent strategic acquisition of SOLV's Purification and Filtration business, which was valued at $4.1 billion, analysts are optimistic about the stock. According to its long-term growth strategy, the acquisition is expected to improve Thermo Fisher Scientific Inc. (NYSE:TMO)'s reputation in the bioprocessing industry, particularly infiltration. Puneet Souda, an analyst at Leerink Partners, gave the business a Buy recommendation on February 27 and has remained bullish about it. Due to several circumstances surrounding its purchase of SOLV's Purification and Filtration division, he has assigned the stock this rating. The analyst predicts that the deal will become accretive over time, with a good return on invested capital by the fifth year. Overall TMO ranks 3rd among the innovative healthcare stocks to watch in 2025. While we acknowledge the potential of TMO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TMO but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Sign in to access your portfolio
Yahoo
17-04-2025
- Business
- Yahoo
Boston Scientific Corporation (BSX): Among the Innovative Healthcare Stocks to Watch in 2025
In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private health insurance is the two leading causes of this increase. The impact of tariffs on this continuing trend has become a significant bone of contention in the healthcare industry as more and more US corporations turn to China for agreements on the next breakthrough chemical, whether in the areas of obesity or cancer. Carlo Rizzuto, managing director of Versant Ventures, spoke on CNBC's "Fast Money" on February 7 about the impact of tariffs on healthcare. Rizzuto says that tariffs may impact the sector in two ways. Products made in China and sold in the US or other countries would be the first. The industry would need to watch how the tariffs are used in the market to comprehend how they would impact such trade operations. Second, and more precisely, the US healthcare industry relies heavily on China as a basis for contract production and research. Consequently, anything that raises that price is probably going to make the market more difficult. Cost hikes won't help the healthcare industry's management, which is already under pressure from investors. Speaking on China's enormous impact in the pharmaceutical and healthcare sectors, Rizzuto said that the vast majority of healthcare companies use a Chinese CRO or manufacturing partner in some capacity during the research and development phase. As a result, it significantly affects how the nation's biotech and pharmaceutical industries function. This trend is rather common in businesses of all sizes. In other words, the lack of infrastructure to facilitate the transfer prevents healthcare corporations from reshoring all of their externalized R&D and production to the United States. Therefore, it is hard to imagine how such a large-scale reshoring might occur. The amount of tariffs imposed can be used to determine the expenses of achieving this objective linearly. According to McKinsey, healthcare EBITDA will rise from a starting point of $676 billion in 2023 to $987 billion in 2028 at a 7% CAGR. Recovery from post-pandemic lows is anticipated to spur progress in several areas, even though development is anticipated to be faster in some (such as specialized pharmacy and HST). Software platforms are essential to the healthcare ecosystem because they let payers and providers operate more effectively in a complex environment. By automating procedures, fostering data connectivity, and producing actionable insights, technological innovation (such as generative AI and machine learning) keeps providing opportunities for stakeholders from all industries. McKinsey predicts that increased utilization and pipeline expansion (as in cancer) will result in a considerable increase in specialty pharmacy income. Specialty pharmacy profit pools are continuing to grow as a result of the rise in the use of specialty medications. For this article, we began by screening the top holdings of the iShares U.S. Healthcare ETF (IYH) to focus on prominent companies within the U.S. healthcare sector. From this list, we selected the top 10 holdings based on their weight in the ETF portfolio. We then ranked these stocks according to the number of hedge funds holding positions in each company as of Q4 2024, based on data from Insider Monkey's hedge fund tracking database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A surgeon examining a patient's brain in an operating room, paramedics nearby. Number of Hedge Fund Holders: 96 The fifth stock on our list of the best healthcare stocks is Boston Scientific Corporation (NYSE:BSX). It is a Massachusetts-based company that specializes in developing, manufacturing, and distributing medical devices for interventional procedures worldwide. It is divided into two sections: Cardiovascular and MedSurg. Citing the company's impressive fourth-quarter earnings, Canaccord Genuity raised the price objective from $101 to $117 on February 6 and kept its Buy rating on the shares. In the fourth quarter of 2024, Boston Scientific Corporation (NYSE:BSX) recorded net sales of over $4.6 billion, a 22.4% increase over the same time the previous year. Compared to $504 million, or $0.34 per share, in the previous year, GAAP net income attributable to common stockholders increased to $566 million, or $0.38 per share. Adjusted EPS for Q4 increased from $0.55 to $0.7. Net sales for 2024 as a whole came to $16.75 billion, representing a 17.6% increase over the previous year. Boston Scientific Corporation (NYSE:BSX) announced on March 3 that it has reached a final deal to buy the privately held medical device startup SoniVie Ltd. The TIVUS Intravascular Ultrasound System, an experimental device created by SoniVie, is intended to treat hypertension disorders by targeting the nerves that surround blood vessels. Overall BSX ranks 5th among the innovative healthcare stocks to watch in 2025. While we acknowledge the potential of BSX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BSX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below.
